The bill clarifies and broadens patent eligibility for many machine- and biotech-related inventions—boosting predictability and investment—while increasing the potential for broader patents, higher licensing costs, more litigation over borderline claims, and uneven protection for software and nature-based innovations.
Researchers, inventors, and small businesses will face clearer patent-eligibility rules, reducing uncertainty when filing, prosecuting, and enforcing patents.
Tech companies, inventors, and investors in machine- or computer-assisted technologies will gain broader eligibility for patents, encouraging investment and commercialization of machine-dependent inventions.
Biotech and pharmaceutical innovators (researchers, hospitals) can patent engineered, purified, enriched, isolated, or otherwise altered genes and natural materials, protecting many processed natural-substance inventions.
Small businesses, consumers, and downstream firms could face higher costs because broader patenting—particularly of software and machine-implemented inventions—may increase licensing fees and transactional burdens.
Tech workers, startups, and financial firms may lose or have reduced patent protection for economic, financial, social, cultural, or artistic processes (including many software- and AI-driven methods), weakening incentives and IP value for those innovations.
Taxpayers, courts, and the USPTO could face greater workloads and more weak patents because courts are restricted from using novelty/nonobviousness/enablement (§§102/103/112) to inform eligibility, shifting substantive vetting away from later stages.
Based on analysis of 4 sections of legislative text.
Replaces judicial exceptions to patent eligibility with a statutory rule making most useful inventions patent-eligible while listing specific exclusions (math, pure mental processes, unmodified human genes/natural materials, mainly business/social processes).
Makes most inventions explicitly eligible for U.S. patents by removing judicially created exceptions to patent eligibility and replacing the current §101 standard with a statutory rule that any useful process, machine, manufacture, composition of matter, or useful improvement is eligible unless specifically excluded. It preserves novelty, nonobviousness, and specification requirements (sections 102, 103, 112) as separate substantive tests but bars their use to defeat eligibility under §101. Creates statutory exclusions for purely mathematical formulas not part of a claimed statutory category, mental processes done solely in a human mind, unmodified human genes and unmodified natural materials as they exist in nature, and predominantly economic/financial/business/social/cultural/artistic processes. Clarifies eligibility for inventions that require machines and narrows when adding routine computer activity can cure ineligibility.
Official title: Amend title 35, United States Code, to address matters relating to patent subject matter eligibility, and for other purposes.
Introduced May 1, 2025 by Thomas Roland Tillis · Last progress May 1, 2025